Bruker and 10x Genomics settle all global patent litigation with cross-license agreements

BRUKER CORP

Settlement resolves all patent disputes between Bruker and 10x Genomics, including multiple litigations in US, Germany, and European Unified Patent Court.
All ongoing lawsuits and administrative proceedings will be withdrawn under global patent cross license agreements.
Bruker's CosMx and GeoMx spatial biology platforms no longer face litigation risk; company can focus on research.
No financial terms of settlement disclosed; parties entered into cross-license agreements.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.